NOW APPROVED
IMCIVREE
IMCIVREE is the first treatment for obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. IMCIVREE has helped people 6 years of age and older lose weight and keep it off.
IMCIVREE should not be used for obesity due to suspected POMC, PCSK1, or LEPR deficiency not confirmed by genetic testing (benign or likely benign result), nor other types of obesity, including those associated with other genetic syndromes and general obesity.
IMCIVREE is the first treatment for obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. IMCIVREE has helped people 6 years of age and older lose weight and keep it off.
IMCIVREE should not be used for obesity due to suspected POMC, PCSK1, or LEPR deficiency that is classified as benign or likely benign, nor other types of obesity, including those associated with other genetic syndromes and general obesity.